hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06387862, orgStudyIdInfo id: 2022SIMBIOV, briefTitle: Pharmacokinetics of Inhaled Levosimendan, acronym: Symbiov, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-20, primaryCompletionDateStruct date: 2024-11, completionDateStruct date: 2025-01, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Universitair Ziekenhuis Brussel, class: OTHER, descriptionModule briefSummary: Determination of biological availability, time-to-peak and elimination half-life of inhaled levosimendan by administration of an inhaled- and intravenous dose of levosimendan., conditionsModule conditions: Left Ventricular Dysfunction, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 6, type: ESTIMATED, armsInterventionsModule interventions name: Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Inhaled, interventions name: Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Intravenous, outcomesModule primaryOutcomes measure: Bioavailability of inhaled levosimendan, primaryOutcomes measure: Time-to-peak of inhaled levosimendan, primaryOutcomes measure: Elimination half-life of inhaled levosimenan, secondaryOutcomes measure: Effect of inhaled levosimendan on MAP, secondaryOutcomes measure: Effect of inhaled levosimendan on TVR, secondaryOutcomes measure: Effect of inhaled levosimendan on CO, secondaryOutcomes measure: Effect of inhaled levosimendan on LVOT VTI, secondaryOutcomes measure: Effect of inhaled levosimendan on FAC of the right vetricle, secondaryOutcomes measure: Effect of inhaled levosimendan on S', secondaryOutcomes measure: Effect of inhaled levosimendan on SPAP, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UZ Brussel, city: Brussel, zip: 1090, country: Belgium, contacts name: Matthias Raes, MD, role: CONTACT, phone: 024749872, email: matthias.raes@uzbrussel.be, contacts name: Marie-Claire Van Malderen, SC, role: CONTACT, phone: 024763110, email: marieclaire.vanmalderen@uzbrussel.be, geoPoint lat: 50.85045, lon: 4.34878, hasResults: False
protocolSection identificationModule nctId: NCT06387849, orgStudyIdInfo id: 03/2023, briefTitle: Aromatherapy Effect on Pain and Anxiety After C-section, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-04-21, primaryCompletionDateStruct date: 2023-08-31, completionDateStruct date: 2023-08-31, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: University Tunis El Manar, class: OTHER, descriptionModule briefSummary: A prospective randomized triple blinded study conducted in the obstetrics gynecology department of Ben Arous hospital over a period of four months and 10 days between April 2023 and August 2023.The aim of this study was to evaluate the effectiveness of lavender aromatherapy on postoperative pain and anxiety after cesarean section under spinal anesthesia in Tunisian women., conditionsModule conditions: Post-operative Pain, conditions: Post-operative Anxiety, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ACTUAL, armsInterventionsModule interventions name: Aromatherapy, interventions name: Placebo, outcomesModule primaryOutcomes measure: Post-operative pain level, primaryOutcomes measure: Post-operative anxiety level, secondaryOutcomes measure: Heart Rate (HR), secondaryOutcomes measure: Systolic Blood Pressure (SBP), secondaryOutcomes measure: Diastolic Blood Pressure (DBP), secondaryOutcomes measure: Respiratory Rate (RR), secondaryOutcomes measure: Pulsatile Oxygen Saturation, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Ben Arous Regional Hospital, city: Ben Arous, country: Tunisia, geoPoint lat: 36.75306, lon: 10.21889, hasResults: False
protocolSection identificationModule nctId: NCT06387836, orgStudyIdInfo id: B2024-063, briefTitle: LINC01844 as a Diagnostic Biomarker for POCD in Elderly Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-21, primaryCompletionDateStruct date: 2025-02-21, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Shanghai Zhongshan Hospital, class: OTHER, descriptionModule briefSummary: Postoperative cognitive dysfunction (POCD) is a common complication after surgery that is associated with more adverse events and death. The goal of this observational study is to learn about the diagnosis performance of long intergenic non-coding RNA(LINC01844) level in blood of older people for POCD. The main question it aims to answer is:Does the relative level of LINC01844 in blood help diagnose POCD of older people after surgery? Participants undergoing elective lumbar decompression and fusion will finish neuropsychological evaluations one day before and 1st, 3rd and 5th day after surgery. At the same timepoint, the relative level of LINC01844 in blood will also be tested., conditionsModule conditions: Postoperative Cognitive Dysfunction, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 63, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: relative level of LINC01844, secondaryOutcomes measure: serum reactive protein-C, secondaryOutcomes measure: serum interleukin-6, eligibilityModule sex: ALL, minimumAge: 65 Years, maximumAge: 85 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zhongshan Hospital Fudan University, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200032, country: China, contacts name: Danfeng Jin, M.D., role: CONTACT, phone: +8613795306154, email: jindanfeng0506@163.com, contacts name: Shengjin Ge, Ph.D., role: CONTACT, phone: +8613601926171, email: ge.shengjin@zs-hospital.sh.cn, contacts name: Shengjin Ge, Ph.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06387823, orgStudyIdInfo id: K5321, briefTitle: Efficacy and Safety of Sivelestat Sodium and Dexamethasone in the Treatment of ARDS, acronym: STAR, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-27, primaryCompletionDateStruct date: 2025-06-01, completionDateStruct date: 2025-09-01, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Peking Union Medical College Hospital, class: OTHER, collaborators name: Peking University, collaborators name: Shanghai Huilun Pharmaceutical Co., Ltd., descriptionModule briefSummary: The goal of this clinical trial is to evaluate the efficacy and safety of Sivelestat sodium and dexamethasone in the treatment of patients with moderate to severe ARDS. The main questions it aims to answer are:* Is Sivelestat sodium more effective in the treatment of patients with moderate to severe ARDS compared with placebo?* Is dexamethasone more effective in the treatment of patients with moderate to severe ARDS compared with placebo? Participants will receive Sivelestat sodium, dexamethasone or placebo. Researchers will compare the efficacy and safety of Sivelestat sodium, dexamethasone and placebo., conditionsModule conditions: Acute Respiratory Distress Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Sivelestat sodium, interventions name: Dexamethasone, interventions name: Sivelestat sodium placebo, interventions name: Dexamethasone placebo, outcomesModule primaryOutcomes measure: 28-day ventilator-free days, primaryOutcomes measure: Informed consent rate, primaryOutcomes measure: Recruitment rate, primaryOutcomes measure: Recruitment compliance rate, primaryOutcomes measure: Protocol adherence rate, primaryOutcomes measure: Completion of follow-up visits, secondaryOutcomes measure: 28-day mortality, secondaryOutcomes measure: 90-day mortality, secondaryOutcomes measure: 28-day length of stay, secondaryOutcomes measure: 28-day organ support free day, secondaryOutcomes measure: Sequential organ failure assessment (SOFA), secondaryOutcomes measure: Murray's acute lung injury score, secondaryOutcomes measure: C-reactive protein (CRP), secondaryOutcomes measure: Interleukin-6 (IL-6), secondaryOutcomes measure: Interleukin-8 (IL-8), secondaryOutcomes measure: Procalcitonin (PCT), secondaryOutcomes measure: Neutrophil-to-lymphocyte Ratio (NLR), secondaryOutcomes measure: Neutrophil elastase, secondaryOutcomes measure: New-onset infection rate, secondaryOutcomes measure: Re-intubation rate, secondaryOutcomes measure: Adverse event, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06387810, orgStudyIdInfo id: MA-PC-II-010, briefTitle: Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer, acronym: undetermined, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-17, primaryCompletionDateStruct date: 2026-04-30, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Peking Union Medical College Hospital, class: OTHER, descriptionModule briefSummary: This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of irinotecan liposome II in combination with oxaliplatin and 5-FU/LV in perioperative treatment of borderline resectable pancreatic cancer in 45 patients., conditionsModule conditions: Borderline Resectable Pancreatic Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: irinotecan liposome II combined with 5-FU/LV and oxaliplatin, outcomesModule primaryOutcomes measure: event free survival, secondaryOutcomes measure: overall survival, secondaryOutcomes measure: R0 resection rate, secondaryOutcomes measure: R1 excision rate, secondaryOutcomes measure: adverse event, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 110 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06387758, orgStudyIdInfo id: UMMC-IRB-2022-473, briefTitle: Low Systemic/High Local Exercise Load in Peds SCD, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-19, primaryCompletionDateStruct date: 2025-06-30, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: University of Mississippi Medical Center, class: OTHER, collaborators name: University of Alabama at Birmingham, descriptionModule briefSummary: This research study wants to learn about what kind of exercise is best for kids with sickle cell disease. Participating children will have a small amount of blood drawn one time at the beginning of the study. Children will then complete some questionnaires that measure pain, physical function, and emotions (depression, anxiety) and complete some tests that measure physical fitness at the beginning and end of the study. Children will be randomized to either a home-based telehealth (1) walking or (2) strengthening exercise program that lasts for 8-weeks, 3-x week, for 45 minutes each session. Children's participation will last up to 10 weeks., conditionsModule conditions: Sickle Cell Anemia in Children, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: FACTORIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Low systemic strength training, interventions name: Moderate systemic exercise, outcomesModule primaryOutcomes measure: Demographics and medical history (parents), primaryOutcomes measure: Pediatric Pain Questionnaire, primaryOutcomes measure: Functional Disability Inventory, primaryOutcomes measure: NIH PROMIS 2582, primaryOutcomes measure: Heart Rate Variability, primaryOutcomes measure: Heart Rate, primaryOutcomes measure: Blood Pressure, primaryOutcomes measure: Bruininks-Oseretsky Test of Motor Proficiency, primaryOutcomes measure: American Thoracic Society 6-minute walk test, primaryOutcomes measure: Actigraphy, primaryOutcomes measure: Daily diaries, primaryOutcomes measure: Biomarkers, primaryOutcomes measure: Medical Chart Review, eligibilityModule sex: ALL, minimumAge: 12 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: University of Mississippi Medical Center, status: RECRUITING, city: Jackson, state: Mississippi, zip: 39216, country: United States, contacts name: Cynthia Karlson, PhD, role: CONTACT, phone: 601-984-2723, email: ckarlson@umc.edu, geoPoint lat: 32.29876, lon: -90.18481, hasResults: False
protocolSection identificationModule nctId: NCT06387745, orgStudyIdInfo id: US-REFERRAL, briefTitle: Referral of Patients to Hepatology With Hepatoscope, acronym: US-REFERRAL, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: University Hospital, Antwerp, class: OTHER, collaborators name: E-Scopics, descriptionModule briefSummary: Patients identified as being at risk of liver fibrosis because of a positive Fibrosis-4 (FIB-4) test in the primary care setting will be offered be enrolled in the trial and to undergo an Hepatoscope exam (external non-invasive ultrasound imaging exam) to screen for liver fibrosis (with stiffness measurements) and/or steatosis (with ultrasound parameters related to fatty liver). All patients presenting with a liver stiffness value of at least 6.5 kilopascal (kPa) will be referred to the tertiary hepatology consultations for further assessment. Hepatoscope measurements will be compared to the standard of care for these patients, as defined at the tertiary hepatology center., conditionsModule conditions: Chronic Liver Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Hepatoscope, outcomesModule primaryOutcomes measure: Positive Predictive Value for significant fibrosis, secondaryOutcomes measure: Correlation of stiffness measurements, secondaryOutcomes measure: Concordance of stiffness measurements, secondaryOutcomes measure: Diagnostic performance of liver stiffness measurements, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06387706, orgStudyIdInfo id: GAP, briefTitle: The Development of a Gamified Web-based Pain Management Program (GAP) for Community-dwelling Older Adults With Chronic Pain, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-01, primaryCompletionDateStruct date: 2024-07-30, completionDateStruct date: 2024-11-30, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: The Hong Kong Polytechnic University, class: OTHER, descriptionModule briefSummary: Pain Management in Older Adults: Pain significantly impacts the well-being of older adults, often leading to diminished physical abilities and a reduced quality of life. Despite this, pain management remains suboptimal, with concerns about medication side effects and a tendency to view pain as a natural aspect of aging. Consequently, many seniors are hesitant to use painkillers. As an alternative, non-pharmacological strategies such as educational programs, physical activity, massage, relaxation techniques, and music therapy are gaining traction.Innovative Non-Drug Solutions: To improve participation in non-medication pain relief methods, we suggest incorporating gaming elements into these programs (GAP). Originating in digital media in 2008, gamification has since spread across various industries. It involves adding game-like elements to activities to boost engagement, experience, and motivation.Project Goals: The aims of this initiative include creating a web-based Gamified Pain Management Program (GAP), engaging older adults with chronic pain in the development of GAP, and gathering their feedback on the program's effectiveness., conditionsModule conditions: Chronic Pain Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 4, type: ESTIMATED, armsInterventionsModule interventions name: Gamified web-based pain management Program, outcomesModule primaryOutcomes measure: Pain Relief, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hong Kong Metropolitan University, status: RECRUITING, city: Hong Kong, country: Hong Kong, contacts name: Mimi Mun Yee Tse, PhD., role: CONTACT, phone: (852)39708764, email: mmytse@hkmu.edu.hk, contacts name: Mimi Mun Yee Mimi Mun Yee, PhD., role: PRINCIPAL_INVESTIGATOR, contacts name: Tyrone Tai On Kwok, PhD., role: SUB_INVESTIGATOR, contacts name: Timothy Chung Ming Wu, Master, role: SUB_INVESTIGATOR, geoPoint lat: 22.27832, lon: 114.17469, hasResults: False
protocolSection identificationModule nctId: NCT06387680, orgStudyIdInfo id: 2022/187, briefTitle: The Peanut Ball Use on Labor, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2024-03-01, completionDateStruct date: 2024-04-01, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Selcuk University, class: OTHER, descriptionModule briefSummary: The purpose of this study was to evaluate the effect of using peanut balls during labor on labor memory, labor satisfaction, labor length, and neonatal APGAR scores., conditionsModule conditions: Birth Outcome, Adverse, conditions: Birth, First, conditions: Labor Long, conditions: Apgar; 4-7 at 1 Minute, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 140, type: ACTUAL, armsInterventionsModule interventions name: The Effect of Peanut Ball Use on Labor Memory, Labor Satisfaction, Delivery Length, and Neonatal APGAR Score: A Randomized Controlled Trial, outcomesModule primaryOutcomes measure: Comparison of sociodemographic of pregnant women., primaryOutcomes measure: Comparison of obstetric characteristics of pregnant women, primaryOutcomes measure: Comparison of postpartum characteristics of pregnant women, primaryOutcomes measure: Comparison of duration of 1st and 2nd stage of labor by group, primaryOutcomes measure: Comparison of 1st and 5th minute APGAR scores of newborns by group, primaryOutcomes measure: Comparison of the mean scores of the Pregnant Women's Birth Memory and Recall Questionnaire (BirthMARQ) and its subscales by groups, primaryOutcomes measure: Comparison of pregnant women's Birth Satisfaction Scale (BSS) mean scores by groups, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Selcuk University, city: Konya, zip: 42250, country: Turkey, geoPoint lat: 37.87135, lon: 32.48464, hasResults: False
protocolSection identificationModule nctId: NCT06387667, orgStudyIdInfo id: FIRTI, briefTitle: Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-12-01, completionDateStruct date: 2026-06-01, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: New Valley University, class: OTHER, descriptionModule briefSummary: Immunocompromised individuals face a heightened risk of life-threatening fungal infections, which arise from a multitude of environmental and commensal fungi. Surveillance data from ICUs worldwide identifies Candida spp. as the dominant foe, responsible for 80% of such infections, earning it the dubious distinction of being the third most prevalent pathogen. While C. albicans holds the dubious crown as the most common Candida offender, recent years have witnessed a concerning trend toward non-Albicans candida, raising concerns about potential antifungal resistance., conditionsModule conditions: Immunocompromised ICU Patients With Respiratory Tract Infections, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Immunocompromised ICU Patients with Respiratory tract infections, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 250, type: ESTIMATED, armsInterventionsModule interventions name: Complete blood count, interventions name: C-reactive protein, urea, creatinine, Random blood glucose (RBG), aspartate aminotransferase (AST), alanine aminotransferase (ALT), interventions name: CT chest, interventions name: Microscopic examination, interventions name: culture and sensitivity, outcomesModule primaryOutcomes measure: Number of fungal species causing pneumonia in immunocompromised ICU patients, secondaryOutcomes measure: Determine the antifungal susceptibility profiles of the identified fungal isolates., secondaryOutcomes measure: Number of associated specific patient factors with the type or antifungal resistance of fungal infections, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False